Immuneering (IMRX) Chief Legal Officer acquires 1,020 shares

Rhea-AI Filing Summary

Immuneering Corp (IMRX) Chief Legal Officer and Secretary Michael D. Bookman reported a personal purchase of 1,020 shares of Class A common stock on 10/01/2025 at a price of $6.8299 per share. Following the transaction, Mr. Bookman beneficially owns 4,870 shares. The Form 4 was signed on 10/02/2025 and lists his role as an officer and director. No derivative transactions or additional remarks were reported on the filing.

Positive

• Officer purchase disclosed: Michael D. Bookman acquired 1,020 shares at $6.8299, showing insider buying activity
• Timely and complete Form 4: Transaction date, price, and post-transaction ownership are reported and the form is signed

Negative

• None.

Insights

Financial Analyst

TL;DR: Officer purchase of 1,020 shares at $6.8299 increases insider stake to 4,870 shares; transaction is small but signals insider buying.

The reported purchase is a straightforward non-derivative acquisition by a named officer. The absolute size (1,020 shares) and resulting total holding (4,870 shares) are modest and likely immaterial to company capitalization. For investors, this is a routine disclosure that shows the officer acquired shares at a disclosed price, but it does not, by itself, indicate a material change in control, compensation structure, or corporate strategy.

Corporate Governance Expert

TL;DR: Filing complies with Section 16 reporting; purchase reported timely with manual signature, no governance concerns disclosed.

The Form 4 appears properly completed: it identifies the reporting person, relationship to the issuer, transaction date, transaction code, number of shares acquired, price, and post-transaction beneficial ownership. There are no amendments, derivative positions, or explanatory remarks attached. From a governance perspective, the filing shows compliance with disclosure requirements but contains no material governance events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bookman Michael

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER, SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/01/2025		P		1,020	A	$6.8299	4,870	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Michael D. Bookman	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did IMRX insider Michael D. Bookman report on Form 4?

He reported a purchase of 1,020 Class A common shares on 10/01/2025 at a price of $6.8299 per share.

How many IMRX shares does Michael Bookman own after the transaction?

Following the reported transaction he beneficially owns 4,870 shares of Class A common stock.

What role does the reporting person hold at IMRX?

The Form 4 lists Michael D. Bookman as a Director and as an Officer with titles Chief Legal Officer, Secretary.

When was the Form 4 signed and filed?

The signature on the Form 4 is dated 10/02/2025; the transaction date reported is 10/01/2025.

Were any derivative securities reported in this Form 4 for IMRX?

No derivative securities were reported; Table II contains no entries and only a non-derivative purchase is listed.